PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference

Rhea-AI Summary

PhaseBio Pharmaceuticals (NASDAQ: PHAS), a biopharmaceutical company focused on cardiovascular therapies, announced that CFO John Sharp will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on April 14, 2022, from 1:30 to 2:10 PM ET. The event will be held virtually, and interested parties can access the live and archived webcasts on the company's website. PhaseBio is known for its novel pipeline, including bentracimab and PB6440, aimed at improving treatment outcomes in cardiovascular diseases.

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Financial Officer John Sharp will participate in a fireside chat at the 21st Annual Needham Healthcare Conference taking place virtually on Thursday, April 14, 2022 from 1:30 – 2:10 pm ET.

Interested parties can access the live and archived webcasts of the virtual session on the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases. The Company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005866/en/

PhaseBio Investor Contact:

John Sharp

Chief Financial Officer

(610) 981-6506

john.sharp@phasebio.com

PhaseBio Media Contact:

Will Zasadny

Canale Communications, Inc.

(619) 961-8848

will.zasadny@canalecomm.com

Source: PhaseBio Pharmaceuticals, Inc.

FAQ

When is John Sharp participating in the Needham Healthcare Conference for PhaseBio Pharmaceuticals?

John Sharp will participate in the Needham Healthcare Conference on April 14, 2022, from 1:30 to 2:10 PM ET.

How can I access the PhaseBio Pharmaceuticals conference webcast?

The webcast can be accessed live and archived on the 'Events and Presentations' page of PhaseBio's website.

What are the key products in PhaseBio Pharmaceuticals' pipeline?

PhaseBio's pipeline includes bentracimab, a reversal agent for ticagrelor, and PB6440, an oral treatment for resistant hypertension.

Where is PhaseBio Pharmaceuticals located?

PhaseBio Pharmaceuticals is located in Malvern, PA, and San Diego, CA.

What is the focus of PhaseBio Pharmaceuticals?

PhaseBio is focused on developing and commercializing novel therapies for cardiovascular diseases.